Comparison	O
of	O
FOLFIRINOX	B:C0879464
Chemotherapy	O
with	O
Other	O
Regimens	O
in	O
Patients	O
with	O
Biliary	O
Tract	I:C0750952
Cancers	I:C0750952
:	O
a	O
Retrospective	O
Study	I:C0035363
.	O

Comparison	O
of	O
FOLFIRINOX	O
Chemotherapy	B:C3665472
with	O
Other	O
Regimens	O
in	O
Patients	O
with	O
Biliary	O
Tract	I:C0750952
Cancers	I:C0750952
:	O
a	O
Retrospective	O
Study	I:C0035363
.	O

Comparison	O
of	O
FOLFIRINOX	O
Chemotherapy	O
with	O
Other	O
Regimens	B:C0040808
in	O
Patients	O
with	O
Biliary	O
Tract	I:C0750952
Cancers	I:C0750952
:	O
a	O
Retrospective	O
Study	I:C0035363
.	O

Comparison	O
of	O
FOLFIRINOX	O
Chemotherapy	O
with	O
Other	O
Regimens	O
in	O
Patients	O
with	O
Biliary	B:C0750952
Tract	I:C0750952
Cancers	I:C0750952
:	O
a	O
Retrospective	O
Study	I:C0035363
.	O

Comparison	O
of	O
FOLFIRINOX	O
Chemotherapy	O
with	O
Other	O
Regimens	O
in	O
Patients	O
with	O
Biliary	O
Tract	I:C0750952
Cancers	I:C0750952
:	O
a	O
Retrospective	B:C0035363
Study	I:C0035363
.	O

The	O
aim	O
of	O
this	O
retrospective	B:C0035363
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	B:C0683525
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	B:C0206698
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	B:C0206698
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	B:C1171558
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	B:C0045093
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	B:C0045093
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	B:C1171558
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	B:C0016360
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	B:C0016360
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	B:C0879464
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	B:C0879464
)	O
chemotherapy	O
.	O

The	O
aim	O
of	O
this	O
retrospective	O
study	I:C0035363
was	O
to	O
compare	O
the	O
different	O
treatment	O
options	I:C0683525
of	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
(	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
)	O
who	O
were	O
treated	O
with	O
platinum	O
-	O
gemcitabine	O
(	O
CG	O
)	O
or	O
platinum	O
-	O
5	O
-	O
fluorouracil	O
(	O
CF	O
)	O
or	O
5	O
-	I:C0879464
Fluorouracil	I:C0879464
-	I:C0879464
oxaliplatin	I:C0879464
-	I:C0879464
irinotecan	I:C0879464
(	O
FOLFIRINOX	O
)	O
chemotherapy	B:C3665472
.	O

We	O
included	O
the	O
patients	O
with	O
advanced	O
biliary	B:C0206698
tract	I:C0206698
carcinoma	I:C0206698
who	O
were	O
registered	O
at	O
the	O
Department	O
of	I:C0587443
Oncology	I:C0587443
in	O
Gaziantep	O
University	I:C0041740
between	O
January	O
2008	O
and	O
January	O
2016	O
.	O

We	O
included	O
the	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
who	O
were	O
registered	B:C1514821
at	O
the	O
Department	O
of	I:C0587443
Oncology	I:C0587443
in	O
Gaziantep	O
University	I:C0041740
between	O
January	O
2008	O
and	O
January	O
2016	O
.	O

We	O
included	O
the	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
who	O
were	O
registered	O
at	O
the	O
Department	B:C0587443
of	I:C0587443
Oncology	I:C0587443
in	O
Gaziantep	O
University	I:C0041740
between	O
January	O
2008	O
and	O
January	O
2016	O
.	O

We	O
included	O
the	O
patients	O
with	O
advanced	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
who	O
were	O
registered	O
at	O
the	O
Department	O
of	I:C0587443
Oncology	I:C0587443
in	O
Gaziantep	B:C0041740
University	I:C0041740
between	O
January	O
2008	O
and	O
January	O
2016	O
.	O

The	O
following	O
data	O
were	O
analyzed	B:C0936012
:	O
disease	O
control	I:C0920467
rate	O
(	O
DCR	O
)	O
,	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
first	O
and	O
second	O
-	I:C1710038
line	I:C1710038
of	O
chemotherapy	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
following	O
data	O
were	O
analyzed	O
:	O
disease	B:C0920467
control	I:C0920467
rate	O
(	O
DCR	O
)	O
,	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
first	O
and	O
second	O
-	I:C1710038
line	I:C1710038
of	O
chemotherapy	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
following	O
data	O
were	O
analyzed	O
:	O
disease	O
control	I:C0920467
rate	O
(	O
DCR	O
)	O
,	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
first	B:C1708063
and	O
second	O
-	I:C1710038
line	I:C1710038
of	O
chemotherapy	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
following	O
data	O
were	O
analyzed	O
:	O
disease	O
control	I:C0920467
rate	O
(	O
DCR	O
)	O
,	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
first	O
and	O
second	B:C1710038
-	I:C1710038
line	I:C1710038
of	O
chemotherapy	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

The	O
following	O
data	O
were	O
analyzed	O
:	O
disease	O
control	I:C0920467
rate	O
(	O
DCR	O
)	O
,	O
progression	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
first	O
and	O
second	O
-	I:C1710038
line	I:C1710038
of	O
chemotherapy	B:C3665472
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

Kaplan	O
-	O
Meier	O
method	O
and	O
Log	B:C0237913
-	I:C0237913
rank	I:C0237913
test	I:C0237913
was	O
used	O
to	O
compare	O
two	O
survival	O
curves	O
,	O
and	O
hazard	O
regression	I:C0033489
model	I:C0033489
was	O
used	O
to	O
evaluate	O
risk	O
factors	I:C0035648
for	O
PFS	O
.	O

Kaplan	O
-	O
Meier	O
method	O
and	O
Log	O
-	I:C0237913
rank	I:C0237913
test	I:C0237913
was	O
used	O
to	O
compare	O
two	O
survival	O
curves	O
,	O
and	O
hazard	B:C0033489
regression	I:C0033489
model	I:C0033489
was	O
used	O
to	O
evaluate	O
risk	O
factors	I:C0035648
for	O
PFS	O
.	O

Kaplan	O
-	O
Meier	O
method	O
and	O
Log	O
-	I:C0237913
rank	I:C0237913
test	I:C0237913
was	O
used	O
to	O
compare	O
two	O
survival	O
curves	O
,	O
and	O
hazard	O
regression	I:C0033489
model	I:C0033489
was	O
used	O
to	O
evaluate	B:C0220825
risk	O
factors	I:C0035648
for	O
PFS	O
.	O

Kaplan	O
-	O
Meier	O
method	O
and	O
Log	O
-	I:C0237913
rank	I:C0237913
test	I:C0237913
was	O
used	O
to	O
compare	O
two	O
survival	O
curves	O
,	O
and	O
hazard	O
regression	I:C0033489
model	I:C0033489
was	O
used	O
to	O
evaluate	O
risk	B:C0035648
factors	I:C0035648
for	O
PFS	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	B:C0332154
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
regimen	O
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	B:C0045093
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
regimen	O
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	O
,	O
CF	B:C0016360
,	O
and	O
FOLFIRINOX	O
regimen	O
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	B:C0879464
regimen	O
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
regimen	B:C0040808
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
regimen	O
as	O
first	B:C1708063
-	I:C1708063
line	I:C1708063
chemotherapy	O
,	O
respectively	O
.	O

53	O
(	O
57.6	O
%	O
)	O
,	O
27	O
(	O
29.3	O
%	O
)	O
,	O
and	O
12	O
(	O
13	O
%	O
)	O
patients	O
received	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
regimen	O
as	O
first	O
-	I:C1708063
line	I:C1708063
chemotherapy	B:C3665472
,	O
respectively	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	B:C0045093
group	O
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	O
group	O
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	O
group	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	O
group	B:C1257890
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	O
group	O
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	O
group	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	O
group	O
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	B:C0016360
group	O
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	O
group	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	O
group	O
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	O
group	B:C1257890
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	O
group	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	O
group	O
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	O
group	O
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	B:C0879464
group	O
.	O

Median	O
PFS	O
and	O
DCR	O
of	O
CG	O
group	O
were	O
22	O
weeks	O
and	O
56.6	O
%	O
,	O
and	O
these	O
were	O
12	O
weeks	O
and	O
44.4	O
%	O
for	O
CF	O
group	O
,	O
and	O
9	O
weeks	O
and	O
41.7	O
%	O
for	O
FOLFIRINOX	O
group	B:C1257890
.	O

Median	O
OS	O
of	O
CG	B:C0045093
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
groups	O
was	O
28	O
,	O
21	O
,	O
and	O
23.5	O
weeks	O
,	O
respectively	O
(	O
p	O
=	O
0.497	O
)	O
.	O

Median	O
OS	O
of	O
CG	O
,	O
CF	B:C0016360
,	O
and	O
FOLFIRINOX	O
groups	O
was	O
28	O
,	O
21	O
,	O
and	O
23.5	O
weeks	O
,	O
respectively	O
(	O
p	O
=	O
0.497	O
)	O
.	O

Median	O
OS	O
of	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	B:C0879464
groups	O
was	O
28	O
,	O
21	O
,	O
and	O
23.5	O
weeks	O
,	O
respectively	O
(	O
p	O
=	O
0.497	O
)	O
.	O

Median	O
OS	O
of	O
CG	O
,	O
CF	O
,	O
and	O
FOLFIRINOX	O
groups	B:C1257890
was	O
28	O
,	O
21	O
,	O
and	O
23.5	O
weeks	O
,	O
respectively	O
(	O
p	O
=	O
0.497	O
)	O
.	O

Second	B:C1710038
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
group	O
and	O
gemcitabine	O
-	O
based	O
chemotherapy	O
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	B:C0596581
-	O
based	O
chemotherapy	O
group	O
and	O
gemcitabine	O
-	O
based	O
chemotherapy	O
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	B:C3665472
group	O
and	O
gemcitabine	O
-	O
based	O
chemotherapy	O
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
group	B:C1257890
and	O
gemcitabine	O
-	O
based	O
chemotherapy	O
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
group	O
and	O
gemcitabine	B:C0045093
-	O
based	O
chemotherapy	O
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
group	O
and	O
gemcitabine	O
-	O
based	O
chemotherapy	B:C3665472
group	O
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
fluoropyrimidine	O
-	O
based	O
chemotherapy	O
group	O
and	O
gemcitabine	O
-	O
based	O
chemotherapy	O
group	B:C1257890
was	O
12	O
vs.	O
14	O
weeks	O
(	O
p	O
=	O
0.988	O
)	O
.	O

Second	B:C1710038
-	I:C1710038
line	I:C1710038
PFS	O
of	O
FOLFIRINOX	O
was	O
20	O
weeks	O
,	O
whereas	O
it	O
was	O
14	O
weeks	O
for	O
other	O
fuoropyrimidine	O
-	O
based	O
chemotherapies	O
(	O
p	O
=	O
0.190	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
FOLFIRINOX	B:C0879464
was	O
20	O
weeks	O
,	O
whereas	O
it	O
was	O
14	O
weeks	O
for	O
other	O
fuoropyrimidine	O
-	O
based	O
chemotherapies	O
(	O
p	O
=	O
0.190	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
FOLFIRINOX	O
was	O
20	O
weeks	O
,	O
whereas	O
it	O
was	O
14	O
weeks	O
for	O
other	O
fuoropyrimidine	B:C0596581
-	O
based	O
chemotherapies	O
(	O
p	O
=	O
0.190	O
)	O
.	O

Second	O
-	I:C1710038
line	I:C1710038
PFS	O
of	O
FOLFIRINOX	O
was	O
20	O
weeks	O
,	O
whereas	O
it	O
was	O
14	O
weeks	O
for	O
other	O
fuoropyrimidine	O
-	O
based	O
chemotherapies	B:C3665472
(	O
p	O
=	O
0.190	O
)	O
.	O

This	O
was	O
the	O
first	O
study	B:C0008972
evaluating	O
the	O
FOLFIRINOX	O
regimen	O
in	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
.	O

This	O
was	O
the	O
first	O
study	O
evaluating	B:C0220825
the	O
FOLFIRINOX	O
regimen	O
in	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
.	O

This	O
was	O
the	O
first	O
study	O
evaluating	O
the	O
FOLFIRINOX	B:C0879464
regimen	O
in	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
.	O

This	O
was	O
the	O
first	O
study	O
evaluating	O
the	O
FOLFIRINOX	O
regimen	B:C0040808
in	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
.	O

This	O
was	O
the	O
first	O
study	O
evaluating	O
the	O
FOLFIRINOX	O
regimen	O
in	O
biliary	B:C0206698
tract	I:C0206698
carcinoma	I:C0206698
.	O

Cisplatin	B:C0338265
-	I:C0338265
gemcitabine	I:C0338265
therapy	O
still	O
provides	O
better	O
survival	O
in	O
BCT	O
.	O

Cisplatin	O
-	I:C0338265
gemcitabine	I:C0338265
therapy	B:C0087111
still	O
provides	O
better	O
survival	O
in	O
BCT	O
.	O

Cisplatin	O
-	I:C0338265
gemcitabine	I:C0338265
therapy	O
still	O
provides	O
better	O
survival	O
in	O
BCT	B:C0206698
.	O

However	O
,	O
FOLFIRINOX	B:C0879464
can	O
be	O
an	O
option	O
in	O
the	O
second	O
-	I:C1710038
line	I:C1710038
treatment	I:C1710038
of	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
patients	O
who	O
are	O
eligible	O
for	O
chemotherapy	O
.	O

However	O
,	O
FOLFIRINOX	O
can	O
be	O
an	O
option	O
in	O
the	O
second	B:C1710038
-	I:C1710038
line	I:C1710038
treatment	I:C1710038
of	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
patients	O
who	O
are	O
eligible	O
for	O
chemotherapy	O
.	O

However	O
,	O
FOLFIRINOX	O
can	O
be	O
an	O
option	O
in	O
the	O
second	O
-	I:C1710038
line	I:C1710038
treatment	I:C1710038
of	O
biliary	B:C0206698
tract	I:C0206698
carcinoma	I:C0206698
patients	O
who	O
are	O
eligible	O
for	O
chemotherapy	O
.	O

However	O
,	O
FOLFIRINOX	O
can	O
be	O
an	O
option	O
in	O
the	O
second	O
-	I:C1710038
line	I:C1710038
treatment	I:C1710038
of	O
biliary	O
tract	I:C0206698
carcinoma	I:C0206698
patients	O
who	O
are	O
eligible	O
for	O
chemotherapy	B:C3665472
.	O

